The current $195 million investment is part of a commitment to invest more than $10 billion for innovation and manufacturing capacity enhancement.

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Abbott Laboratories spinoff AbbVie will ...

AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

The new North Chicago facility, slated to open in 2027, will boost domestic production of key drug ingredients for immunology ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a study titled ‘A Randomized ...

Drugmaker AbbVie plans to construct a $195 million facility near its headquarters in North Chicago to manufacture active pharmaceutical ingredients, The Chicago Tribune reported Aug. 12. Construction ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

AbbVie (NYSE: ABBV) has unveiled a $195 million investment to expand its North Chicago manufacturing plant to include domestic active pharmaceutical ingredient (API) production. The expansion is part ...

The global biopharma firm will build a new API production facility near its global headquarters in North Chicago.

"AbbVie expands North Chicago API production with $195m investment" was originally created and published by Pharmaceutical ...

AbbVie to invest $195m in US API manufacturing expansion as pharma rushes to boost domestic capacity ahead of expected drug ...